hotspot -WSS

hotspot

author：fashion 2025-10-03 01:03:49 - browse：95599

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Eli Lilly expects to double planned employment in Boston center

focus

WSS

FDA gives detailed accounting of AI

STAT Summit: Biotech founders on deal

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Will Ozempic

FDA reorg will put new emphasis on investigations, sources say

Beam Therapeutics to lay off 20% of its staff, re

leisure time

hotspot

Wikipedia

Peter Hotez and the public health issue of online harassment

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Medical records are filled with copy

Weight loss drugs should be covered by insurers, AMA says

In Memoriam: Notable people who died in 2023

The explosion of genetic testing requires a new approach

Malaria cases in Florida and Texas: Here’s what you need to know

First Opinion Podcast: Long Covid needs a new approach

Medical leaders decry Supreme Court decision on affirmative action

2023 STAT Wunderkinds: get to know the winners

hotspot

STAT Summit: How a Chicago ER doctor tackles gun violence

Experimental asthma app from Apple and Anthem shows promise

STAT Summit: GSK CEO on pharma giant's new direction

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Studies point to risks of excluding people with obesity from drug trials

Ventyx halts psoriasis drug development after lackluster trial results

entertainment

focus

hotspot

explore